485 related articles for article (PubMed ID: 22520124)
21. Issues with reducing the rotavirus-associated mortality by vaccination in developing countries.
Naghipour M; Nakagomi T; Nakagomi O
Vaccine; 2008 Jun; 26(26):3236-41. PubMed ID: 18472196
[TBL] [Abstract][Full Text] [Related]
22. Rotavirus vaccines: targeting the developing world.
Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
[TBL] [Abstract][Full Text] [Related]
23. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
25. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
[TBL] [Abstract][Full Text] [Related]
26. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.
Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Kallen L; Atherly D
Lancet Glob Health; 2019 Dec; 7(12):e1664-e1674. PubMed ID: 31708147
[TBL] [Abstract][Full Text] [Related]
27. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
Kim SY; Sweet S; Slichter D; Goldie SJ
BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
30. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
[TBL] [Abstract][Full Text] [Related]
31. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
Patel MM; Clark AD; Glass RI; Greenberg H; Tate J; Santosham M; Sanderson CF; Steele D; Cortese M; Parashar UD
Vaccine; 2009 May; 27(22):2916-22. PubMed ID: 19428901
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
[TBL] [Abstract][Full Text] [Related]
34. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
Shim E; Galvani AP
Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
[TBL] [Abstract][Full Text] [Related]
35. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of a routine rotavirus vaccination programme in Indonesia.
Wilopo SA; Kilgore P; Kosen S; Soenarto Y; Aminah S; Cahyono A; Ulfa M; Tholib A
Vaccine; 2009 Nov; 27 Suppl 5():F67-74. PubMed ID: 19931723
[TBL] [Abstract][Full Text] [Related]
37. Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality.
Tate JE; Patel MM; Cortese MM; Lopman BA; Gentsch JR; Fleming J; Steele AD; Parashar UD
Expert Rev Vaccines; 2012 Feb; 11(2):211-20. PubMed ID: 22309669
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
39. Potential cost-effectiveness of a rotavirus immunization program in rural China.
Wang XY; Riewpaiboon A; von Seidlein L; Chen XB; Kilgore PE; Ma JC; Qi SX; Zhang ZY; Hao ZY; Chen JC; Xu ZY
Clin Infect Dis; 2009 Oct; 49(8):1202-10. PubMed ID: 19739973
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children.
Chotivitayatarakorn P; Chotivitayatarakorn P; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):114-25. PubMed ID: 20578490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
